Athos Therapeutics, Inc., a Los Angeles, CA-based late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, closed a $15m Series A financing.
The backers were not disclosed.
Led by Dimitrios Iliopoulos, PhD, MBA, President & Chief Executive Officer, and Allan J. Pantuck, MD, MS, Chairman and Chief Medical Officer, Athos Therapeutics is a late-stage preclinical biotech company developing small molecule therapeutics for immune-mediated diseases and cancer using artificial intelligence-generated innovative chemistry and computational platforms. Athos identifies novel drug targets (hubs) by integrating clinical and molecular datasets into the biological network of a disease (the disease interactome) and matches them to its small molecule computational chemistry platform. ATH-63, the company’s lead drug compound, is moving into a Phase Ia human clinical early in 2022. The pipeline includes small molecule approaches for various autoimmune disease and cancer.
The funding will be used to advance the company’s pre-clinical and clinical programs, including the initiation of a first in human phase I clinical trial of ATH-63 in 2022. Athos is developing ATH-63 for Inflammatory Bowel Disease, Lupus, other autoimmune disorders, and select cancer indications. Funding will also be used to develop additional novel targets for autoimmune diseases and two first-in-class small molecule inhibitors for solid cancers and AML. Additionally, Athos will further advance its proprietary artificial intelligence drug discovery platform, and substantially expand its patient biomaterial omics database through collaborations with large academic medical centers all over the world, including the Cleveland Clinic Foundation.